Drug Trial Radar · NCT07561645
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Apr 2032
Study completion Apr 2032
Sponsor
- Lead sponsor
- Technische Universität DresdenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Conditions
- Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
ObrixtamigDrug
Obrixtamig (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Three cycles of combined immunochemotherapy 3qw will be followed by maintenance with obrixtamig monotherapy until progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: app. 69 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.